Member Info for Trinityman

Struggling to find the right words here… I find it absolutely incredible that a group of intelligent, experienced investors would even consider engaging with an individual who:

A. Tells the board there should be an EGM then:
B. Tells you to go away and arrange it, then:
C. Start scaremongering with a ‘running out of cash’ thread.

This from someone who doesn’t attend AGMs – Seriously?

A supposed business owner who can find the time to post 17 times in 24 hours. Believe me, business owners don’t have the time to post 17 times a month, let alone a day.
Also, the accountant who prepares my annual accounts for my small business charges by the half hour. You won’t find me talking idly about AIM shares to him when the clock is ticking, nor would any other credible business owner or accountant worth their salt.

Once again, as for the best part of 2022, you have been ‘sucked into the vortex’, keeping this individual front and centre of the board, the centre of attention yet again, exactly as planned and over what?

Absolutely nothing.

The fact is there is NO EMERGENCY.

SNG are recruiting for a ‘HEAD OF US COMMERCIAL OPERATIONS’.

They wouldn’t be advertising this post if they weren’t planning on selling the drug for profit - They just wouldn’t. Sprinter taught both SNG and investors a harsh lesson, we all know we only have one more shot at this and they have to get it right, they are not stupid.

In 2021 they recruited this gent:
‘Richard Francis joined as Head of CMC, bringing more than 35 years of experience in the development, manufacturing, regulatory approval and COMMERCIALISATION of many biopharmaceutical products including Cablivi®, Orthoclone OKT3®, Remicade®, and ReoPro®.’

Yes, he’s manufactured and sold drugs on a large commercial scale before. Guess why SNG hired him? Still here.

In the same year they also recruited this guy:

‘Richard Hennings, previously worked for Verona Pharma, Gildead Sciences, Novartis + Astra Zeneca. During his 8 year Gilead tenure he led the expansion of respiratory & anti-viral portfolios in the EU & US markets, launching inhaled Cayston®.’

Guess what? He’s still here as well.

Successful high flyers like this don’t ruin their CVs or waste their working lives on a tin pot company with a drug that won’t ever see the light of day – They just don’t.

Added to that they’re recruiting a head of COMMERCIAL operations in the US.

The fact that they’re still here should inspire a small degree of guarded confidence. With the cash burn now greatly reduced, there is no need to storm the gate with pitchforks and lighted torches.

Most remaining posters have been badly burnt here, but remain with varying degrees of guarded optimism. Give the board until the Spring to deliver news, then if none arrives a re-think would certainly be required.
Either plans are at an advanced stage or they’re blowing smoke up your …. All the evidence points to the former.

(Cont above)..

Maybe Ghia could return to add some meat onto the 'value generating' bones as 7/02 draws near?

Fruits - I'll add you to my notebook - not sure which section though.

Tommy - Ditch the therapy and buy some more shares - that way you'll make back more of the 100k you lost 12 months ago, they're a steal at under 14p.

RM has to give Katie some good news soon surely?

ATVB T

From my notes:

Ghia @ 00.11 on 20/11/22:

‘2023 is nearby I’ll sharpen my prediction to February for value generating news on or after the 7th.’

As tomorrow is the 7th – thoughts anyone?

This is supposed to be a discussion board.

I’ll catch up with any insight this evening – Some of us still have to go out there and keep the wheels turning!

ATVB T

Busterboy - I'm as sure as any retail investor can be that this won't go the same way as SXX.

There is every reason to remain cautiously optimistic that we will eventually see a healthy return on our investment, although the route to market is as yet unknown.
The key word is 'eventually', I feel we'll have news in Q1, so not too long to wait now.
Although we all have differing views, at the end of the day at least 95% of board members all want to see this drug on the shelves one way or another.
All the very best to you and all long term holders.

Many thanks to Fruits, Gunto, AnthonyW, Tommy, DocD, Paladin and Jackman for your considered replies and imput to my earlier post – much appreciated.

As Gunto says, it’s good to have a reasonable debate and I guess an individual’s level of trust and expectation depends largely on previous experience with AIM shares. Doc83’s 14.56 post being as good an example as any.

I clearly remember the first hand accounts of the final meeting in London between shareholders and the BOD of SXX. There were security guards with dogs at that altercation and with good reason, so a certain degree of the ‘I’ll believe it when I see it’ attitude is understandable in some cases.

Totally across fruit’s observation of the BOD keeping their cards close to their chest, but I don’t and never have agreed with CEOs only speaking when they have something that materially affects the share price or only when they are forced to at AGMs. One of the functions of a CEO is to keep investors in the loop and not left reading between the lines.

I think a quarterly or bi-monthly update on general progress, next steps, rationale behind recent hires etc without going into fine detail is required. I feel total radio silence is not acceptable and shows a lack of respect to LTHS. I know at this stage we are now at the bottom of the food chain, having been courted by presentations etc in the early stages, but that’s AIM for you.
The level of frustration builds when there are long periods of silence and the drift in share price does nothing to quell the fears of the less experienced investor. This stance also leaves the board wide open to the ‘manipulators’ who don’t have investor’s or the company’s best interests at heart. A regular, brief update would put an end to that.

SNG haven’t really found their niche to market yet, COPD – covid – and now talk of multi-purpose trials. It would be good to see STRIVE covid P3 completed, as it has taken so long to get here, although I appreciate the appeal of a JV/BP collaboration with more control over the protocol/ endpoints is also appealing.
The networking and the mood music has been positive across the pond and the ‘alternative therapeutics’ drum is beating, but now the time draws near where words have to be put into action.

As an aside, I had my page view with everyone de-filtered during the past year for research purposes on human behaviour, jeez there’s some excellent case study material on here isn’t there? More on that over the weekend if time permits.

ATVB T

#royaltyenginehahaha

The debate currently being held on this forum is mainly due to RM’s ‘multiple arrows’ comment, as the term is so vague it is open to interpretation and has left investors without a clearly defined pathway to success. As we know the market hates uncertainty, which has been reflected in the declining share price, leaving LTHs the target for ridicule from a minority of flawed characters on this board.

Given the rarity of public comment out of Southampton HQ, you would imagine when one of them eventually speaks it would be with absolute clarity, but not in this case, Richard loves to keep us hanging on in there with obtuse phrases.
One of my less charitable investment buddies, who uses more ‘industrial’ language interpreted the comment as, ‘throw so much $hit at the wall, hoping some of it will stick.’ Hard to argue with that viewpoint at the time.

It would have been beneficial if Marsden had clearly specified whether they were aiming for several trials running simultaneously, or one single entity involving many more patients treating a ‘broad spectrum’ at the same time, with varying results running side by side.
Gunto reckons there is now clarity regarding this, but nothing is certain as IMO the American’s will ultimately make the decision.

A ‘broad spectrum’ treatment is obviously the Nirvana that all pharma companies aspire to, but in reality there is always the small matter of FDA clearance to overcome. Anyone who has been invested with other pharma companies will know this is a long, tedious process that generally takes 1-2 years to complete.

I am not cross ramping here, but I will mention Angle PLC, as they have recently completed the tortuous process of FDA approval.
They have a new piece of tech that offers early detection of cancer without the need for biopsy, but when they initially opened up discussions with the FDA to seek advice on the pathway forward they were advised to study and obtain results for breast cancer only, followed by separate studies and results for ovarian, prostate and so on.
They were specifically advised that approval to sell their tech to cover all cancer types was out of the question from day one.

I obviously highlight this as there is a clear parallel to be drawn with SNG’s ‘broad spectrum’ approach. Given this scenario, I'm hoping, no at this stage, praying that we secure a place on the STRIVE covid P3 bandwagon. Decent P3 results here - The rest should follow.

Several posters have voiced concerns that we would lose control over the protocol, endpoints etc, but at this point we have little choice but to put our trust in the Americans, as we lost control over our own destiny after Sprinter and whether we like it or not, the USA hold the cards that matter. They have the cash, the BPs and the FDA.

There is enough evidence to suggest that SNG will be included on STRIVE P3, as they have clearly stated the treatment ‘merits further investigation’, whether Strive P3 materialises only time wil

TommyD –
How do you even find the nerve to address Ghia in 2023 after your appalling ‘Kermit and Miss Piggy’ double act over the summer?
Do you think board members have memories of goldfish?
In any other sphere your posts and those of ‘the woman’ from June onwards would have been classed as shameful online abuse.
Your online dalliance with your now mercifully absent online buddy reached truly nauseating levels at times, repeatedly goading Ghia for merely putting forward the view that shareholders should tuck their certificates away in the ‘bottom drawer’, as there would be no significant share price movement into well into the following year, a view has been entirely vindicated as we moved into 2023.
For some unknown reason, you morphed from the resident, useful science geek into one half of a grotesque online bullying tag team.
As Ghia said some time ago, ‘Most of the science has been done now’, so your role here is now becoming increasingly redundant.
Your latest comment, ‘so many of your posts have a bias that’s rather one sided this year’ – Listen to yourself. The words ‘pot’ and ‘kettle’ come to mind.
Ghia’s a smart guy and can defend himself, but pontificating from the elevated perch on which you have placed yourself these days puts you in a bad light with anyone who has read these pages over the past year.
It’s about time you got off the guy’s back, your stance is getting more tedious with each post.
Stick to your speciality and leave it at that - the science.

Spacman:

‘My suspicion is that all the actors are in place; Rick Bright and De La Cruz would not be risking their reputations on some remote UK one-drug business with a $30m market cap unless there was BP in the wings. And my guess is Johnson & Johnson, why would they be funding the Universal observational trial otherwise?... certainly not to provide data for a competitor to use.’

Andybe4:

Totally implausible.
However nicely written.
I even suspect an element of desperation from the rampers of this stock suggesting a SPAC.
It’s total delusion.

Synairgen – Latest vacancy description:

‘The Associate Medical Affairs Director is responsible for managing Synairgen’s relationships with external medical stakeholders, to enable evaluation & preparation for the introduction of SNG001 into clinical practice, post Regulatory approval.’

Spac? – JV? – Strive P3? – PT? – Dilution?

All we have at present are suspicions, guesses, differing viewpoints, fence sitting and attritional posts – Oh and the sand in the egg timer is running out.

The silence is deafening..C’mon Marsden, it’s about time you followed this guy’s lead:

Geraint Anderson, CEO of TT electronics plc: “You must have regular dialogue with investors and analysts to build trust and credibility. You need, first of all, for the investors to understand your strategy and then you need to build their confidence as you execute that strategy. You need also to be very clear in setting the expectations as you will always be judged on what you said you will do.”

https://www.criticaleye.com/archive.cfm?id=332

DocD -

I think the backlash to FTC was mainly down to his use of the phrase 'rubbish stock', a view to which he is perfectly entitled and also to be challenged.

I believe the varying levels of bullishness regarding the activity SNG has carried out over the last 11 months is down to lack of concrete information, leaving the current position open to interpretation - reading between the lines etc.

As time goes by, views tend to split into two camps, causing bickering and frustration.

Totally agree we need news on Strive one way or another. There has been no evidence to suggest we won't be included and enough to suggest we should.

The longer retail investors are sidelined by the company, the more uncertainty grows. Not long to wait now I suspect.

ATVB T.

DocD -

I always take note of your posts, as most are usually well worth reading and generally contain credible, well presented viewpoints. However, many are presented as fact, not personal opinion.

For example:

'...hardly anything in Brysoa's long treatise is correct.'

Maybe you could include, 'in my opinion' at the end of that sentence, for much of what is in discussion we are not yet privy to, if indeed it exists at all.

I can't remember the poster from last week who used a phrase similar to, 'the company are leaving a trail of breadcrumbs for us to follow', but they were obviously referring to the range of activities behind the scenes that have taken place since last February’s debacle.

Whether the endless networking, schmoozing, hiring, presenting etc amounts to anything we’ll soon find out.

We’re either being led down a very long garden path and being deliberately kept in the dark or our patience will eventually be rewarded by some concrete news leading to a re-rate in the share price.

Although I have a degree of loyalty to the potential of the drug and the founder, I’m becoming increasingly tired by Marsden’s reluctance to update the humble retail investor.

I have no interest in weekly communications regarding what biscuits are on the tea trolley, but a ten minute overview of the current situation wouldn’t go amiss at this stage.

I’d be interested in your view regarding the percentage chance of eventually turning a profit here, or not as the case may be. No worries if you don't wish to quantify your thoughts in such a manner.

ATVB T

Brysoa -

Re Your 14.49 - Post of the month by a country mile.

Thank you for succinctly summarising the many snippets and thoughts that swirl in and out of my brain regarding SNG during a busy working week and even more so over the weekend - I doubt I am alone in this respect.

In general, I'd say I was a 'conviction investor', an individual who believes in the product, technology or service an individual company provides and am quite prepared to play the long game in regard to my investment.

Having being unlucky enough to suffer from severe respiratory illness from the age of seven until the age of thirty (now well controlled due to several new drug developments over the decades) I have a particular interest in the success of SNG.

I realise this can be classed as 'emotional attachment', not recommended when investing , but in this case the evidence provided to date is so compelling I'm staying to the end, whatever the outcome.

Having said all that, this is not a 'done deal' by any means at this stage. The road to commercialisation will be rocky to say the least.

For one, A USA democratic government won't look too kindly on a small UK pharma coming to the world's rescue - They have to be seen to play that role and there are political barriers to overcome for sure, let's hope the influential American medical players can use their influence in getting this over the line on our behalf.

I think we will have a clearer picture before the end of Q1.

ATVB T

Synnerman -
Having been on this page for roughly three years now, I know the cast of characters well, some have agendas, some have genuine concerns and some are simply damaged individuals who don't handle life in the real world well, so migrate online onto boards like this.

I'm politely asking the guy to back off a little, now the daily ramping/ abuse of other posters has ended.
If that doesn't work - fair enough, you know it's 100% agenda driven trolling.

ATVB

Macosta/ Mr Costs:

Taking away the amusing daily spats with Dunk, your multiple aliases and your purported large shareholding, I’ll take a rare and more measured response to your 100% negative stance regarding the dismal performance of SNG.

I fully understand your outlook and I’ll give you the benefit of the doubt that the constant and excessive repetition of your views throughout 2022 was a response to the sheer number of positive and completely vacuous posts from one particular poster (currently absent), whose behaviour (IMO) closely mirrored that of an individual who suffered from not one, but two personality disorders.
Mercifully these have ceased in 2023, only time will tell whether this is a temporary or permanent situation.

Like many, I found the state of this board during much of 2022 to be a source of constant frustration and annoyance and I realise you were merely attempting to redress the balance.

As the board has now returned to some degree of normality and reasoned discussion, could you limit your constant negative posts to weekly instead of daily from now on?

Not trying to gag you, free speech is precious, but keeping up this level of constant negativity puts you in a bad light.
You are clearly articulate and some of what you say carries weight, it would do more so if you posted the same message less often.

Your post (below) from 13th September didn’t really help your credibility rating did it?
Less content and more reasoned substance from today onwards please. If you don’t have any, don’t post.

‘Jannsen - this amazing collaboration don't even want us for the world beating drug, they want to use some office desks or whatever it is.’

Truly one of the low points of 2022 on here and that is really saying something.

T

Vertis? This is no time for latin Doc. :)

Strive was always going to be the key - Will SNG finally be allowed permission to unlock the potential here?

How big will the collective sigh of relief be on this board if correct?
They'll probably here it across the pond.

ATVB T

Paladin –
Very few posters would disagree with your views in relation to narcissistic behaviour.

However, it is easy to focus only on those that have negative views and ignore or simply miss the narcissist(s) who relentlessly post positive views (trolling in plain sight), which distorts the situation to new or inexperienced investors looking for genuine insight.

I recall a previous poster who had a very similar, almost unique writing style to your own who was the recipient of a very confrontational, attritional post from such an individual last year, causing them to cease posting.

I noted with interest you started posting a month or so after this unsavoury incident, your summaries and balanced views of the situation are always a welcome read.

The poster ‘Waiteoxford’ earlier today used the term ‘squabblefest’.

This was the root cause of the poor quality of this board for much of 2022, certainly during the summer, often descending into chaos - A squabblefest indeed. Any new posters would have decided this was no place to obtain any sort of decent analysis or balanced viewpoint.

It was good to see a mature, balanced debate here over the weekend, a welcome return to the informed discussion we used to see during the initial phase 2 trial period. Only 10 – 15 posts a day back then, similar figures today during this limbo week.

Interesting to note that the share price dipped to circa 35p at the time, but now with so much more positive data we are now languishing at this current low level.

Obviously SNG are now classed by the majority of investors as ‘damaged goods’ after their failed trial. They simply cannot afford to get it wrong next time.

I’m aligned with your view that we’ll see a positive outcome here, but wary of the many headwinds between now and then.
Wishing you and all holders a successful year ahead.

Just to rub salt in our wounds, 'Proactive Investors' have published their end of year stats showing the best and worst performing AIM shares for 2022.

With over 800 shares on the AIM market, SNG came in the bottom ten.

The best performing share in 2022 gave investors a healthy + 304% return.

From today's lowly level, this would only take us to 55.75p
Leaving most investors still well underwater.

Dog or star share in 2023??
I think we'll find out before the daffodils begin flowering.

https://www.proactiveinvestors.co.uk/companies/news/1002143/aim-stars-and-flops-prospex-wins-the-2022-blue-riband-1002143.html

Welcome back BG - Really good to see you posting again.

ATVB T

Since that truly gut wrenching day back on 21st February, there has been mounting evidence to suggest that this treatment is safe, effective and well tolerated with absolutely none to the contrary. In addition, specific patient types/ level of illness whereby this treatment can be used most effectively have been identified.

I still hold the view that the logical conclusion of the chances of ‘Synterferon’ actually reaching the lungs of patients going forward from 2023 and beyond is still 90%.

In March 2020 Synairgen had 19 employees, since then the company has morphed from a small research and development company to quasi production within three years. This rate of development is virtually unheard of within the pharma industry and doesn’t happen without good reason.

The fact that Synairgen have still kept their production infrastructure intact (third party contracts, employees etc) should tell you something about the chances of success.

There are many detractors who will describe this view as completely delusional, they may be proved right and have a right to air their views. Time will tell, as at this stage they have the upper hand, as the company face many obstacles and headwinds from here to production, not least the worsening macro-economic conditions and Synairgen’s apparent total lack of influence within political and pharma circles both at home and abroad.

As an aside, I wonder when Viletrader/ Quaser etc’s parents held their newborn in their arms and were musing what might become of them – Lawyer, plumber, street cleaner etc, I doubt the option of ‘keyboard warrior wasting their life online, goading shareholders of a currently beleagured pharma minnow’ was near the top of their list – If only they could see what their efforts amounted to….

I tend not to take the advice of complete strangers on a chat room, instead I prefer to follow those who are slightly more informed and possibly more suitably qualified.

I’m currently aligned to the views taken by Rick Bright, the man who recently held the most senior position within the USA’s Biomedical Advanced Research and Development Authority and holder of a Phd in immunology and molecular pathogenesis, with over 25 years experience in adressing pandemic outbreaks.

It is clear that Bright sees host targeted inhaled antivirals as the way forward and has stated that ‘preparedness’ should begin sooner rather than later. Amen to that.

Dr. Bright or Viletrader? – Your choice.

As a reminder, I’ll leave you with the famous quote from Warren Buffett, one of the most successful investors of all time:
‘The stock market is a device for transferring money from the impatient to the patient’.
Or put another way, ‘This time next year Rodders’.

ATVB T

PS – Many thanks to to The Paladin, Doc and Ghia and twelve other posters for the welcome back after my seven month absence from the board – much appreciated.

About this time of year investors tend to reflect on the performance of their chosen shares.
Whatever your views on the prospects for Synairgen, you have to admit 2022 has been a torrid year for the company.

On Friday 18th February the share price was 171p.
Two weeks later on Friday 4th March the share price had plummeted to 23p.
This effectively took the share price back to levels not seen since March 2020, when I first took an interest.
The losses look even greater if you look back to the high of 246p in August of that year.

171p – 23p equates to an 87% loss in two weeks.
With today’s share price languishing around 17p this now represents a staggering loss of 90%.

To recoup a 90% loss, a gain of 900% must be made to revert to the previous price of circa 170p.
This is the stark reality shareholders face moving into 2023.

I know many have averages much lower than this, but the vast majority are currently well in the red.

With no recent update forthcoming from CEO Marsden regarding the way forward, it is currently difficult to make an accurate assessment of the risk/ reward ratio, leaving LTHs attempting to read between the lines, picking over the minutiae and generally bickering between themselves.

A phase 3 trial, platform trial, joint venture, partnership etc would lead to a significant re-rate of sorts, but as retail investors we can only pluck random figures out of the air.
None of the above would put the share price anywhere near previous highs.

The only event that will take your account from red to green is commercial production.
Until Synairgen actually start selling their product, the share price will not move back into treble figures.

The pharma world moves at a glacial pace and drugs of this magnitude only come to market every thirty years or so. Most AIM investors expect a return within months, not years, leaping about like frogs on a pond from lily pad to lily pad hoping to land on the next ‘big thing’. Patience is a commodity in short supply within this sphere.

The situation is not helped by CEO Marsden’s poor choice of words e.g. ‘pushing hard for results’ and ‘at haste’ to name but two. The lack of updates and complete ‘radio silence’ in between does nothing to quell the nerves and gives the flawed characters on boards such as this the opportunity to sow their seeds of doubt. On the other side of the coin, the incessant vacuous weekly ramping from one particular source has left this board in a sorry state for much of the year.

In February I posted a long article setting out why Synairgen had, in my view, a 90% chance of eventually getting their drug on the shelves after almost two decades of research and development. The change in ‘standard of care’ for patients during the phase 3 trial has now effectively put back the timescale at least two years, with the route to commercialisation still remaining unclear.
(Cont above)..

Conviction Life Sciences - I can vouch for the integrity of their founder.

Andrew Craig who created 'Plain English Finance' some years ago is as honest and straightforward as they come, a refreshing change in the investment world.
I recommend reading his learning materials and website, very easy to digest and doesn't get involved in anything remotely risky.
Very reassuring to see him coming onboard the Angle train.

ATB T.